AF
KNTE

Amalgamated Financial’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Amalgamated Financial’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$36K Buy
+3,172
New +$34.9K ﹤0.01% 2562

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Amalgamated Financial's KNTE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2022: 3,172 shares worth $36K. The stake represents ﹤0.01% of the portfolio and ranks #2562 among its holdings.

76 funds tracked by Wall St. Rank hold KNTE as of Q1 2022.

  • Amalgamated Financial held 3,172 shares of Kinnate Biopharma Inc. Common Stock worth $36K as of Q1 2022.
  • Kinnate Biopharma Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • Kinnate Biopharma Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2562 holding.
  • 76 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.